Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

被引：36

作者：

Awan, Farrukh T. ^{[1
]}

Thirman, Michael J. ^{[2
]}

Patel-Donnelly, Dipti ^{[3
]}

Assouline, Sarit ^{[4
]}

Rao, Arati, V ^{[5
]}

Ye, Wei ^{[5
]}

Hill, Brian ^{[6
]}

Sharman, Jeff P. ^{[7
,8
]}

机构：

[1] Ohio State Univ, Comprehens Canc Ctr, Div Hematol, Columbus, OH 43210 USA

[2] Univ Chicago Med, Dept Hematol Oncol, Chicago, IL USA

[3] Virginia Canc Specialists, Fairfax, VA USA

[4] McGill Univ, Dept Oncol, Med Sch, Montreal, PQ, Canada

[5] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[6] Cleveland Clin, Dept Hematol & Oncol, Cleveland, OH 44106 USA

[7] Willamette Valley Canc Inst & Res Ctr, Springfield, OR USA

[8] US Oncol Res, Springfield, OR USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 08期

关键词：

SYK; B-cell receptor inhibitors; Richter's transformation; IBRUTINIB THERAPY; KINASE INHIBITOR; OUTCOMES; IDELALISIB; RITUXIMAB;

D O I：

10.1080/10428194.2018.1562180

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Entospletinib (GS-9973), an oral, selective inhibitor of spleen tyrosine kinase (SYK), was evaluated as monotherapy in this multicenter, phase 2 study (NCT01799889) of 49 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with Richter's transformation (RT), who had received prior therapy with a B-cell receptor (BCR) inhibitor. Patients were treated with entospletinib 400mg BID as the starting dose. Sixteen patients achieved partial response and 21 had stable disease. The overall response rate was 32.7% (95% confidence interval [CI]: 21.7-45.3%). The median progression-free survival (PFS) was 5.6 (95% CI: 3.7-8.3)months. Twenty-one (of 43) patients (48.8%) experienced nodal response. Adverse events (AEs) occurred in all patients; most commonly fatigue, diarrhea, and anemia. Entospletinib monotherapy has clinical activity for patients with CLL and RT who have relapsed following therapy with BCR inhibitors.

引用

页码：1972 / 1977

页数：6

共 27 条

[1]

[Anonymous], 2016, BLOOD

[2] Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL [J].

Brown, J. R. ;

Hillmen, P. ;

O'Brien, S. ;

Barrientos, J. C. ;

Reddy, N. M. ;

Coutre, S. E. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Delgado, J. ;

Montillo, M. ;

DeVos, S. ;

Moreno, C. ;

Pagel, J. M. ;

Munir, T. ;

Burger, J. A. ;

Chung, D. ;

Lin, J. ;

Gau, L. ;

Chang, B. ;

Cole, G. ;

Hsu, E. ;

James, D. F. ;

Byrd, J. C. .

LEUKEMIA, 2018, 32 (01) :83-91

[3] Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia [J].

Brown, Jennifer R. ;

Byrd, John C. ;

Coutre, Steven E. ;

Benson, Don M. ;

Flinn, Ian W. ;

Wagner-Johnston, Nina D. ;

Spurgeon, Stephen E. ;

Kahl, Brad S. ;

Bello, Celeste ;

Webb, Heather K. ;

Johnson, Dave M. ;

Peterman, Sissy ;

Li, Daniel ;

Jahn, Thomas M. ;

Lannutti, Brian J. ;

Ulrich, Roger G. ;

Yu, Albert S. ;

Miller, Langdon L. ;

Furman, Richard R. .

BLOOD, 2014, 123 (22) :3390-3397

[4] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[5] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[6] Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Harrington, Bonnie ;

O'Brien, Susan ;

Jones, Jeffrey A. ;

Schuh, Anna ;

Devereux, Steve ;

Chaves, Jorge ;

Wierda, William G. ;

Awan, Farrukh T. ;

Brown, Jennifer R. ;

Hillmen, Peter ;

Stephens, Deborah M. ;

Ghia, Paolo ;

Barrientos, Jacqueline C. ;

Pagel, John M. ;

Woyach, Jennifer ;

Johnson, Dave ;

Huang, Jane ;

Wang, Xiaolin ;

Kaptein, Allard ;

Lannutti, Brian J. ;

Covey, Todd ;

Fardis, Maria ;

McGreivy, Jesse ;

Hamdy, Ahmed ;

Rothbaum, Wayne ;

Izumi, Raquel ;

Diacovo, Thomas G. ;

Johnson, Amy J. ;

Furman, Richard R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :323-332

[7] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[8] Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy [J].

Coutre, Steven ;

Choi, Michael ;

Furman, Richard R. ;

Eradat, Herbert ;

Heffner, Leonard ;

Jones, Jeffrey A. ;

Chyla, Brenda ;

Zhou, Lang ;

Agarwal, Suresh ;

Waskiewicz, Tina ;

Verdugo, Maria ;

Humerickhouse, Rod A. ;

Potluri, Jalaja ;

Wierda, William G. ;

Davids, Matthew S. .

BLOOD, 2018, 131 (15) :1704-1711

[9] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia [J].

Furman, Richard R. ;

Sharman, Jeff P. ;

Coutre, Steven E. ;

Cheson, Bruce D. ;

Pagel, John M. ;

Hillmen, Peter ;

Barrientos, Jacqueline C. ;

Zelenetz, Andrew D. ;

Kipps, Thomas J. ;

Flinn, Ian ;

Ghia, Paolo ;

Eradat, Herbert ;

Ervin, Thomas ;

Lamanna, Nicole ;

Coiffier, Bertrand ;

Pettitt, Andrew R. ;

Ma, Shuo ;

Stilgenbauer, Stephan ;

Cramer, Paula ;

Aiello, Maria ;

Johnson, Dave M. ;

Miller, Langdon L. ;

Li, Daniel ;

Jahn, Thomas M. ;

Dansey, Roger D. ;

Hallek, Michael ;

O'Brien, Susan M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) :997-1007

[10] Ibrutinib has some activity in Richter's syndrome [J].

Giri, S. ;

Hahn, A. ;

Yaghmour, G. ;

Martin, M. G. .

BLOOD CANCER JOURNAL, 2015, 5 :e277-e277

← 1 2 3 →